Niramai Health Analytix Pvt Ltd.

Niramai Health Analytix is a pioneering company focused on innovative breast cancer screening through advanced thermal imaging technology integrated with artificial intelligence, aiming to enhance early detection and accessibility of breast health assessments. Founded in 2016 in Bangalore, India, Niramai Health Analytix specializes in the development of AI-powered thermal imaging systems for breast cancer detection. The company was co-founded by Geetha Manjunath and Nidhi Mathur, with Geetha Manjunath serving as CEO. Niramai has participated in 4 funding deals, with the latest being a Series A round where they raised INR 430.

390 mn on June 29, 2021, from investors including Ankur Capital, Axilor Ventures, BEENEXT, Dream Incubator, and pi Ventures. The total amount raised by the company stands at INR 430. 390 mn with a current valuation of INR 1731. 699 mn.

Niramai specializes in advanced breast cancer screening solutions using thermal imaging technology powered by artificial intelligence. The company's flagship product, the SMILE-100 system, has received FDA clearance and is intended for healthcare professionals to analyze thermal images for breast health assessments. Another key product, the Thermalytix device, offers a portable, non-invasive method for early detection of breast cancer, emphasizing affordability and safety. Niramai's solutions are utilized by healthcare providers across various settings, including hospitals and primary clinics, with a target demographic of women aged 18 to 80+.

The company's technology is expanding internationally, aiming to increase accessibility for women in both urban and rural regions. In 2023, Niramai generated revenue of INR 766282. 8, while recording an EBITDA of INR -1415442. 6.

The company generates income primarily through the sale and deployment of its patented breast cancer screening systems, focusing on B2B transactions with healthcare institutions and clinics. Their pricing model encompasses equipment sales in conjunction with ongoing service contracts for maintenance. Revenue is supplemented by partnerships for screening camps and potential collaborations with corporate clients for employee health screening initiatives, enabling competitive pricing across various healthcare settings. Following a venture funding round on June 29, 2021, Niramai plans to utilize the funds to conduct free pilots in public places to enhance their FeverTest product, adapting it for better performance amid crowd movement and COVID safety measures.

The company aims to expand its market presence, targeting new geographic regions and healthcare markets to improve early breast cancer detection accessibility. This strategic initiative aligns with their commitment to developing innovative products that cater to evolving healthcare needs.